| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US5399578 (Pediatric) | NOVARTIS | Acyl compounds |
Sep, 2012
(11 years ago) | |
| US6294197 | NOVARTIS | Solid oral dosage forms of valsartan |
Jun, 2017
(6 years ago) | |
|
US6294197 (Pediatric) | NOVARTIS | Solid oral dosage forms of valsartan |
Dec, 2017
(6 years ago) | |
Diovan Hct is owned by Novartis.
Diovan Hct contains Hydrochlorothiazide; Valsartan.
Diovan Hct has a total of 3 drug patents out of which 3 drug patents have expired.
Expired drug patents of Diovan Hct are:
- US5399578*PED
- US6294197
- US6294197*PED
Diovan Hct was authorised for market use on 06 March, 1998.
Diovan Hct is available in tablet;oral dosage forms.
Diovan Hct can be used as treatment of hypertension.
The generics of Diovan Hct are possible to be released after 18 December, 2017.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-567) | Jul 31, 2011 |
Drugs and Companies using HYDROCHLOROTHIAZIDE; VALSARTAN ingredient
Market Authorisation Date: 06 March, 1998
Treatment: Treatment of hypertension
Dosage: TABLET;ORAL
How can I launch a generic of DIOVAN HCT before it's drug patent expiration?
More Information on Dosage
DIOVAN HCT family patents
